Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer

Jiahao Liu; Xiaofei Jiao; Qinglei Gao

doi:10.1016/j.drudis.2020.04.015

Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer

Drug Discov Today. 2020 Jul;25(7):1232-1238. doi: 10.1016/j.drudis.2020.04.015. Epub 2020 Apr 29.

Authors

Jiahao Liu¹, Xiaofei Jiao¹, Qinglei Gao²

Affiliations

¹ Department of Gynecological Oncology, Tongji Hospital of Huazhong University of Science and Technology, Wuhan, China.
² Department of Gynecological Oncology, Tongji Hospital of Huazhong University of Science and Technology, Wuhan, China. Electronic address: qingleigao@hotmail.com.

PMID: 32360532
DOI: 10.1016/j.drudis.2020.04.015

Abstract

Neoadjuvant chemotherapy (NACT) has been regarded a standard treatment for advanced ovarian cancers for decades. Among patients who are poor candidates for primary debulking surgery (PDS), NACT is likely their only option in clinical practice. However, NACT failed to show any survival benefit in the reported randomized controlled trials (RCTs) and the meta-analyses, compared with PDS. This phenomenon raises concerns over the unfavorable influence of NACT, that is, the potential risk of inducing platinum resistance. In this review, we reveal the risk of NACT-related platinum resistance by summarizing the experimental and clinical evidence and discuss new attempts to avoid this phenomenon.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Drug Resistance, Neoplasm / drug effects*
Female
Humans
Meta-Analysis as Topic
Neoadjuvant Therapy / methods
Organoplatinum Compounds / therapeutic use*
Ovarian Neoplasms / drug therapy*
Randomized Controlled Trials as Topic

Substances

Antineoplastic Agents
Organoplatinum Compounds